This article previously described the ICG100 Onco Focus Panel as a next-generation sequencing test based on an Intermountain press release that erroneously described it as such. The panel uses Agena Bioscience's MassARRAY system, and this article has been updated to reflect that.
Intermountain's Edited Cancer Panel Reducing Rate of Tests Rejected Due to Insufficient Samples
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.